Interaction of bivalent ligand KDN21 with heterodimeric δ-κ opioid receptors in human embryonic kidney 293 cells

Zhihua Xie, Rashmi G. Bhushan, David Daniels, Philip S. Portoghese

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

KDN21 is a bivalent ligand that contains δ and κ opioid antagonist pharmacophores linked through a 21-atom spacer. It has been reported that KDN21 bridges δ and κ receptors that are organized as heterodimers. We have shown previously that when using [3H] diprenorphine as radioligand, KDN21 displayed greatly enhanced affinity in this series for coexpressed δ and κ opioid receptors (CDK). The present study used in vitro expression systems to investigate interactions of members of the KDN series with δ-κ heterodimers through competition binding using selective ligands and the mitogen-activated protein kinase (MAPK) assay. In this regard, the use of the selective radioligands [3H]naltrindole and [3H]norbinaltorphimine (nor-BNI) in competition binding studies revealed that KDN21 has much higher affinity than other KDN members for CDK and bound to CDK more selectively relative to mixed δ and κ opioid receptors or singly expressed δ and κ opioid receptors. Other experiments revealed that the binding of naltrindole to δ opioid receptors could increase the binding of nor-BNI to κ opioid receptors and vice versa, suggesting reciprocal allosteric modulation of receptors in the heterodimer. Regarding the selectivity of KDN21 for phenotypic δ and κ opioid receptors, we investigated the effect of KDN21 on the activation of MAPKs [extracellular signal-regulated kinases 1 and 2 (ERK1/2)] by δ- or κ-selective agonists. KDN21 inhibited the activation of ERK1/2 by [D-Pen2,D-Pen5]-enkephalin (δ1) and bremazocine (κ2) but had no effect on the activation by deltorphin II (δ2) and (+)-(5α,7α,8β)-N- methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]benzeneacetamide (U69593, κ1). 7-Benzylidenenaltrexone (δ1) and bremazocine (κ2) significantly reduced the binding of KDN21 to CDK, whereas naltriben (δ2) and U69593 produced no such change. Taken together, these data support the idea that the organization of δ and κ receptors as heterodimers gives rise to δ1 and κ2 phenotypes.

Original languageEnglish (US)
Pages (from-to)1079-1086
Number of pages8
JournalMolecular Pharmacology
Volume68
Issue number4
DOIs
StatePublished - Oct 2005
Externally publishedYes

Fingerprint

Opioid Receptors
naltrindole
Ligands
Kidney
Mitogen-Activated Protein Kinase 3
Benzeneacetamides
Diprenorphine
MAP Kinase Kinase 2
D-Penicillamine (2,5)-Enkephalin
Narcotic Antagonists
Mitogen-Activated Protein Kinase 1
Mitogen-Activated Protein Kinases
Phenotype

ASJC Scopus subject areas

  • Pharmacology

Cite this

Interaction of bivalent ligand KDN21 with heterodimeric δ-κ opioid receptors in human embryonic kidney 293 cells. / Xie, Zhihua; Bhushan, Rashmi G.; Daniels, David; Portoghese, Philip S.

In: Molecular Pharmacology, Vol. 68, No. 4, 10.2005, p. 1079-1086.

Research output: Contribution to journalArticle

Xie, Zhihua ; Bhushan, Rashmi G. ; Daniels, David ; Portoghese, Philip S. / Interaction of bivalent ligand KDN21 with heterodimeric δ-κ opioid receptors in human embryonic kidney 293 cells. In: Molecular Pharmacology. 2005 ; Vol. 68, No. 4. pp. 1079-1086.
@article{12d3ba4e2e6c4e11a27c558c583ecf58,
title = "Interaction of bivalent ligand KDN21 with heterodimeric δ-κ opioid receptors in human embryonic kidney 293 cells",
abstract = "KDN21 is a bivalent ligand that contains δ and κ opioid antagonist pharmacophores linked through a 21-atom spacer. It has been reported that KDN21 bridges δ and κ receptors that are organized as heterodimers. We have shown previously that when using [3H] diprenorphine as radioligand, KDN21 displayed greatly enhanced affinity in this series for coexpressed δ and κ opioid receptors (CDK). The present study used in vitro expression systems to investigate interactions of members of the KDN series with δ-κ heterodimers through competition binding using selective ligands and the mitogen-activated protein kinase (MAPK) assay. In this regard, the use of the selective radioligands [3H]naltrindole and [3H]norbinaltorphimine (nor-BNI) in competition binding studies revealed that KDN21 has much higher affinity than other KDN members for CDK and bound to CDK more selectively relative to mixed δ and κ opioid receptors or singly expressed δ and κ opioid receptors. Other experiments revealed that the binding of naltrindole to δ opioid receptors could increase the binding of nor-BNI to κ opioid receptors and vice versa, suggesting reciprocal allosteric modulation of receptors in the heterodimer. Regarding the selectivity of KDN21 for phenotypic δ and κ opioid receptors, we investigated the effect of KDN21 on the activation of MAPKs [extracellular signal-regulated kinases 1 and 2 (ERK1/2)] by δ- or κ-selective agonists. KDN21 inhibited the activation of ERK1/2 by [D-Pen2,D-Pen5]-enkephalin (δ1) and bremazocine (κ2) but had no effect on the activation by deltorphin II (δ2) and (+)-(5α,7α,8β)-N- methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]benzeneacetamide (U69593, κ1). 7-Benzylidenenaltrexone (δ1) and bremazocine (κ2) significantly reduced the binding of KDN21 to CDK, whereas naltriben (δ2) and U69593 produced no such change. Taken together, these data support the idea that the organization of δ and κ receptors as heterodimers gives rise to δ1 and κ2 phenotypes.",
author = "Zhihua Xie and Bhushan, {Rashmi G.} and David Daniels and Portoghese, {Philip S.}",
year = "2005",
month = "10",
doi = "10.1124/mol.105.012070",
language = "English (US)",
volume = "68",
pages = "1079--1086",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

TY - JOUR

T1 - Interaction of bivalent ligand KDN21 with heterodimeric δ-κ opioid receptors in human embryonic kidney 293 cells

AU - Xie, Zhihua

AU - Bhushan, Rashmi G.

AU - Daniels, David

AU - Portoghese, Philip S.

PY - 2005/10

Y1 - 2005/10

N2 - KDN21 is a bivalent ligand that contains δ and κ opioid antagonist pharmacophores linked through a 21-atom spacer. It has been reported that KDN21 bridges δ and κ receptors that are organized as heterodimers. We have shown previously that when using [3H] diprenorphine as radioligand, KDN21 displayed greatly enhanced affinity in this series for coexpressed δ and κ opioid receptors (CDK). The present study used in vitro expression systems to investigate interactions of members of the KDN series with δ-κ heterodimers through competition binding using selective ligands and the mitogen-activated protein kinase (MAPK) assay. In this regard, the use of the selective radioligands [3H]naltrindole and [3H]norbinaltorphimine (nor-BNI) in competition binding studies revealed that KDN21 has much higher affinity than other KDN members for CDK and bound to CDK more selectively relative to mixed δ and κ opioid receptors or singly expressed δ and κ opioid receptors. Other experiments revealed that the binding of naltrindole to δ opioid receptors could increase the binding of nor-BNI to κ opioid receptors and vice versa, suggesting reciprocal allosteric modulation of receptors in the heterodimer. Regarding the selectivity of KDN21 for phenotypic δ and κ opioid receptors, we investigated the effect of KDN21 on the activation of MAPKs [extracellular signal-regulated kinases 1 and 2 (ERK1/2)] by δ- or κ-selective agonists. KDN21 inhibited the activation of ERK1/2 by [D-Pen2,D-Pen5]-enkephalin (δ1) and bremazocine (κ2) but had no effect on the activation by deltorphin II (δ2) and (+)-(5α,7α,8β)-N- methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]benzeneacetamide (U69593, κ1). 7-Benzylidenenaltrexone (δ1) and bremazocine (κ2) significantly reduced the binding of KDN21 to CDK, whereas naltriben (δ2) and U69593 produced no such change. Taken together, these data support the idea that the organization of δ and κ receptors as heterodimers gives rise to δ1 and κ2 phenotypes.

AB - KDN21 is a bivalent ligand that contains δ and κ opioid antagonist pharmacophores linked through a 21-atom spacer. It has been reported that KDN21 bridges δ and κ receptors that are organized as heterodimers. We have shown previously that when using [3H] diprenorphine as radioligand, KDN21 displayed greatly enhanced affinity in this series for coexpressed δ and κ opioid receptors (CDK). The present study used in vitro expression systems to investigate interactions of members of the KDN series with δ-κ heterodimers through competition binding using selective ligands and the mitogen-activated protein kinase (MAPK) assay. In this regard, the use of the selective radioligands [3H]naltrindole and [3H]norbinaltorphimine (nor-BNI) in competition binding studies revealed that KDN21 has much higher affinity than other KDN members for CDK and bound to CDK more selectively relative to mixed δ and κ opioid receptors or singly expressed δ and κ opioid receptors. Other experiments revealed that the binding of naltrindole to δ opioid receptors could increase the binding of nor-BNI to κ opioid receptors and vice versa, suggesting reciprocal allosteric modulation of receptors in the heterodimer. Regarding the selectivity of KDN21 for phenotypic δ and κ opioid receptors, we investigated the effect of KDN21 on the activation of MAPKs [extracellular signal-regulated kinases 1 and 2 (ERK1/2)] by δ- or κ-selective agonists. KDN21 inhibited the activation of ERK1/2 by [D-Pen2,D-Pen5]-enkephalin (δ1) and bremazocine (κ2) but had no effect on the activation by deltorphin II (δ2) and (+)-(5α,7α,8β)-N- methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]benzeneacetamide (U69593, κ1). 7-Benzylidenenaltrexone (δ1) and bremazocine (κ2) significantly reduced the binding of KDN21 to CDK, whereas naltriben (δ2) and U69593 produced no such change. Taken together, these data support the idea that the organization of δ and κ receptors as heterodimers gives rise to δ1 and κ2 phenotypes.

UR - http://www.scopus.com/inward/record.url?scp=25144488303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144488303&partnerID=8YFLogxK

U2 - 10.1124/mol.105.012070

DO - 10.1124/mol.105.012070

M3 - Article

VL - 68

SP - 1079

EP - 1086

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 4

ER -